- Home
- ELEV vs XLO Comparison
ELEV vs XLO Comparison
Compare ELEV & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELEV
- XLO
- Stock Information
- Founded
- ELEV 2019
- XLO 2016
- Country
- ELEV United States
- XLO United States
- Employees
- ELEV N/A
- XLO N/A
- Industry
- ELEV Biotechnology: Pharmaceutical Preparations
- XLO Biotechnology: Pharmaceutical Preparations
- Sector
- ELEV Health Care
- XLO Health Care
- Exchange
- ELEV Nasdaq
- XLO Nasdaq
- Market Cap
- ELEV 37.6M
- XLO 42.1M
- IPO Year
- ELEV 2021
- XLO 2021
- Fundamental
- Price
- ELEV $0.66
- XLO $0.83
- Analyst Decision
- ELEV Buy
- XLO Buy
- Analyst Count
- ELEV 6
- XLO 1
- Target Price
- ELEV $7.20
- XLO $4.00
- AVG Volume (30 Days)
- ELEV 4.3M
- XLO 592.2K
- Earning Date
- ELEV 03-05-2025
- XLO 11-07-2024
- Dividend Yield
- ELEV N/A
- XLO N/A
- EPS Growth
- ELEV N/A
- XLO N/A
- EPS
- ELEV N/A
- XLO N/A
- Revenue
- ELEV N/A
- XLO $4,620,000.00
- Revenue This Year
- ELEV N/A
- XLO N/A
- Revenue Next Year
- ELEV N/A
- XLO $368.76
- P/E Ratio
- ELEV N/A
- XLO N/A
- Revenue Growth
- ELEV N/A
- XLO N/A
- 52 Week Low
- ELEV $0.50
- XLO $0.50
- 52 Week High
- ELEV $5.83
- XLO $1.93
- Technical
- Relative Strength Index (RSI)
- ELEV 48.99
- XLO 39.23
- Support Level
- ELEV $0.65
- XLO $0.78
- Resistance Level
- ELEV $0.98
- XLO $1.28
- Average True Range (ATR)
- ELEV 0.12
- XLO 0.13
- MACD
- ELEV -0.01
- XLO -0.02
- Stochastic Oscillator
- ELEV 18.38
- XLO 9.94
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
About XLO Xilio Therapeutics Inc.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).